samedan logo
 
 
spacer
home > ict > autumn 2017 > time to listen
PUBLICATIONS
International Clinical Trials

Time to Listen

The new era of 2.0 technologies has welcomed the science
of pharmacovigilance (PV) with increasing interest from
regulatory agencies, pharmaceutical companies, healthcare
providers and patients, who may be seen as the leaders of
this evolution – as consumers of health-related products, the
collective voice of patients is having a significant impact. This
is contemporary to an observed shift from evidence-based
medicine towards real world evidence and observational
studies. In these, a study’s design is more fitted to patient life
than in controlled clinical trials, where eligible participants
must adapt to study settings.

Social media platforms, like Facebook, Twitter, and
Instagram, along with health-related websites and forums,
such as PatientsLikeMe or pharma-sponsored websites,
offer large forums of expression where any health-related
idea or concern may be shared, including adverse events
attributed to medications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Senior Safety Scientist at UBC, Caroline Legendre is responsible for supporting operational PV functions, including client interface, deliverables related to product safety and safety signal detection and assessment. She has 10 years of experience in the global pharmaceutical industry, with expertise in vaccines, pre- and post-marketing PV and pharmacoepidemiology.

Alexis Pinçon is Safety Physician at UBC and responsible for providing medical support to operational PV functions. He completed his medical training at the University of Lyon, France, and received his Master of Public Health from Université Besançon (Franche-Comté) in 2007. He has 10 years’ experience in PV within the pharma industry, primarily focused on vaccines in both clinical development and post-marketing.
spacer
Caroline Legendre
spacer
spacer
spacer
Alexis Pinçon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

ASPIRE: International EDGE Conference

28 February - 1 March 2018, The Vox Conference Centre, Birmingham

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement